PPI stewardship tightens the case for long-term acid suppression
Proton pump inhibitors remain among the most frequently prescribed drugs in modern practice because they work. In acid-related disorders, few therapies match their ability to reduce symptoms and heal injured mucosa, whether the target is gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, functional dyspepsia, or gastroprotection in patients at high bleeding risk. Their pharmacology is straightforward and powerful: by suppressing gastric acid secretion at the parietal cell, they alter the intragastric environment enough to relieve pain, support mucosal repair, and improve the success of adjunctive therapies used in ulcer disease.
The problem is not the drug class itself. The problem is the duration of exposure drifting far beyond the indications that justified the prescription in the first place.
Long-term exposure has moved beyond the original therapeutic target
Extended PPI use has become common in outpatient medicine, often persisting after the acute reason for treatment has resolved. A patient who needed a short course for erosive disease may stay on the medication for years, sometimes without a documented reassessment of whether ongoing suppression still provides net benefit. That pattern matters because acid suppression is not biologically neutral. When gastric acidity remains chronically reduced, the stomach’s barrier function changes, and the downstream consequences can extend far beyond reflux symptoms.
Observational literature has linked chronic PPI exposure with enteric infections, including Clostridioides difficile, as well as nutrient deficiencies involving magnesium and vitamin B12. Associations have also been reported with osteoporotic fractures, chronic kidney disease, dementia, and gastric and colorectal cancer. These are not proof of causation, and the review is careful on that point. Even so, repeated signals across studies are enough to justify deliberate prescribing, especially when the clinical indication is vague or no longer present.
Safety signals deserve caution even when causality remains uncertain
The strongest argument for stewardship is not alarmism; it is proportion. Patients who truly need a PPI for bleeding prevention, ulcer healing, or refractory reflux should not be denied effective therapy because of observational concerns. But clinicians also should not ignore the possibility that prolonged suppression may contribute to harm in vulnerable groups. Reduced acid can impair mineral absorption, and that mechanism fits the observed association with magnesium and vitamin B12 deficiency. Altered gastric ecology may also facilitate enteric infections, which provides a plausible pathway for the Clostridioides difficile signal seen in chronic users.
Kidney disease and bone outcomes require more caution because confounding is difficult to eliminate in routine clinical datasets. Still, the repeated appearance of these associations in the literature is enough to keep them on the radar during medication review. A long-term prescription should not be treated as a default maintenance drug simply because it has persisted on the chart.
Periodic review is the central intervention
Current guidance favors regular reassessment of ongoing PPI therapy, with deprescribing when the original indication has resolved or when the dose can be reduced safely. In practice, that means asking a simple but often neglected question: does this patient still need full-dose acid suppression every day?
The answer may be yes for patients with severe erosive disease, ulcer complications, Barrett’s esophagus, or a continuing high-risk need for gastroprotection. For others, especially those with non-erosive reflux disease or functional dyspepsia, the medication can often be stepped down. The review describes several strategies: dose reduction, on-demand use, intermittent therapy, and switching to an H2-receptor antagonist when appropriate. Each of these approaches aims to preserve symptom control while minimizing unnecessary exposure.
A short prescription can quietly become a chronic dependency.
Deprescribing works best when the clinical indication is explicit
Stewardship begins before the first refill. Clear documentation of indication, planned duration, and review date makes discontinuation far easier later. Without that structure, therapy often continues by inertia, especially when prescriptions are renewed electronically or inherited across transitions of care. The review points to tools from the National Institute for Health and Care Excellence, the American College of Gastroenterology, and the Canadian Deprescribing Network that help identify candidates for tapering or discontinuation.
Those frameworks matter because they push clinicians to separate two very different situations: a patient with ongoing, evidence-based need for acid suppression, and a patient whose symptoms have settled or whose original risk profile has changed. In the latter group, deprescribing is not therapeutic abandonment. It is medication optimization.
Rebound symptoms can complicate withdrawal
One practical barrier to stopping PPIs is rebound acid hypersecretion. After chronic suppression, the stomach may temporarily increase acid output when the drug is withdrawn, and patients can mistake this rebound for recurrence of the underlying disorder. That feedback loop can drive unnecessary restarting unless the process is explained in advance.
This is where tapering, on-demand use, or a temporary switch to an H2-receptor antagonist can help. For some patients, gradual dose reduction is more tolerable than abrupt cessation. For others, intermittent dosing is sufficient once the acute inflammatory phase has resolved. The right strategy depends on the indication, symptom burden, and the degree of risk attached to recurrence.
Safer prescribing depends on matching intensity to need
The review’s central message is direct: PPIs are highly effective, but they should be used with discipline. Their therapeutic value is strongest when the indication is clear and the duration is appropriate. When use drifts into open-ended maintenance without reassessment, the chance of preventable harm rises while the incremental benefit often shrinks.
That is especially relevant in primary care and gastroenterology clinics where PPIs are among the most common long-term medications. A periodic medication review can identify patients who still need the drug, those who can step down, and those who can stop altogether. In an era of polypharmacy, that kind of review is a safety intervention in its own right.
PPI stewardship ultimately means treating acid suppression like any other long-term therapy: effective when justified, measurable in its benefits, and open to discontinuation when the indication is gone.